DRNAse® Endonuclease

---

DRNAse® Nuclease is encoded by the same gene as Benzonase® from Merck-Millipore. DRNAse® Nuclease is the best choice to reduce the cell lysate viscosity not only in a research laboratory setting but also at a high-scale production of biopharmaceuticals. The enzyme hydrolyzes phosphodiester bonds of oligonucleotides, genomic DNA, RNA, linear, and circular plasmid DNA into very small fragments that are undetectable on an Agarose. The enzyme can be used industrial vaccine development procedures, in reduction of nucleic acid contamination is a regulatory mandate.  The enzyme can efficiently reduce cell viscosity when working with cell lysates on a research scale or at a fermentation-based industrial production leading to reproducible clean results. 

 Isolation of recombinant RNAse-free DNAse I is a Challenge: So far, recombinant DNAse I has been purified from various microbial sources however, DNAse I obtained these sources are not sufficiently free of RNAse activity that it will not compromise the RNA analysis and the final products like mRNA vaccines or mRNA based biologics. Providing a high quality, RNAse-free DNAse I is very critical to Oncosimis® Biotech. Oncosimis® Biotech recombinant DNAse I (rDNAse®) is a secreted endonuclease produced by a microbial fermentation process using BacSec® Technology and E.coli as the host where little to no RNAse activity present. 

Unit Definition: One unit defined as complete cleavage of  1 µg DNA for 10 min at 37°C in a buffer consisting of 10 mM Tris-HCl, pH 7.5, 2.5 mM MgCl 2, 0.5 mM CaCl 2.

Function of rDNAse®:  rDNase® meets or exceeds the performance of competitive DNAse I. It digests DNA to oligonucleotide-sized products or shorter. rDNAse I acts on single- and double-stranded DNA, chromatin and RNA:DNA hybrids without cleaves the RNA which is critical for mRNA-based biologics manufacturing.

Recombinant RNAse-free DNAse I (rDNAse®): Complete digestion of DNA is crucial in production of mRNA vaccine and many other molecular biology techniques. For Instance, mRNA vaccine production requires the removal of template DNA in final product and for accurate quantification of RNA targets by RT-PCR requires the removal of contaminating genomic DNA targets. Oncosimis® Biotech now supplies a recombinant DNAse I (rDNAse®) that is prepared in a technology where little to no RNAse activity present.